Focus Rheums| Dr. Jekyll or Mr. Hyde? (video)

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Teva Pharmaceutical Industries Ltd. News release: Teva and Celltrion announce the availability of Truxima (rituximab-abbs) injection, the first biosimilar to Rituxan (rituximab) in the U.S. 2019 Nov 7.
  2. AbbVie Inc. News release: Rinvoq (upadacitnib) meets primary and all ranked secondary endpoints in phase 3 study in psoriatic arthritis. 2019 Oct 31.

Related Articles

    Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

    As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…